* Immunex Corp., of Seattle, licensed its patented protein granulocyte-colony stimulation factor (G-CSF) receptor to SmithKline Beecham plc, of London, for research and development. Immunex will receive an undisclosed up-front signing fee, milestone and royalty payments, and will retain a stake in any commercial product. G-CSF is a protein that stimulates neutrophil production and mobilizes the hematopoietic progenitor cells into peripheral blood. This growth factor acts by binding to the G-CSF receptor, which was cloned by Immunex.
* Lidak Pharmaceuticals Inc., of San Diego, settled a dispute with Medical Biology Institute, of La Jolla, Calif., over the rights to Lidakol (n-docosanol) Cream — now awaiting FDA approval — as well as three other technologies. Lidak will retain all undisputed rights to n-docosanol cream, a treatment for recurrent oral facial herpes infections, as well as three technologies in the development pipeline. Lidak will lend $500,000 to Medical Biology Institute and return other technologies that no longer fit into Lidak's long-term strategic plans.